SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Australia and internationally.
Reasonable growth potential with adequate balance sheet.
Share Price & News
How has SomnoMed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SOM's share price has been volatile over the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: SOM underperformed the Australian Medical Equipment industry which returned 14.1% over the past year.
Return vs Market: SOM underperformed the Australian Market which returned -18.9% over the past year.
Price Volatility Vs. Market
How volatile is SomnoMed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShorn Like A Sheep: Analysts Just Shaved Their SomnoMed Limited (ASX:SOM) Forecasts Dramatically
2 weeks ago | Simply Wall StCan SomnoMed Limited (ASX:SOM) Improve Its Returns?
1 month ago | Simply Wall StDo Institutions Own SomnoMed Limited (ASX:SOM) Shares?
Is SomnoMed undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SOM (A$1.1) is trading below our estimate of fair value (A$1.85)
Significantly Below Fair Value: SOM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SOM is poor value based on its PE Ratio (78.3x) compared to the Medical Equipment industry average (19.4x).
PE vs Market: SOM is poor value based on its PE Ratio (78.3x) compared to the Australian market (13.3x).
Price to Earnings Growth Ratio
PEG Ratio: SOM is good value based on its PEG Ratio (0.7x)
Price to Book Ratio
PB vs Industry: SOM is overvalued based on its PB Ratio (3.4x) compared to the AU Medical Equipment industry average (3.3x).
How is SomnoMed forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SOM's forecast earnings growth (115.2% per year) is above the savings rate (1.1%).
Earnings vs Market: SOM's earnings (115.2% per year) are forecast to grow faster than the Australian market (10.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SOM's revenue (12.2% per year) is forecast to grow faster than the Australian market (4% per year).
High Growth Revenue: SOM's revenue (12.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SOM's Return on Equity is forecast to be low in 3 years time (8.2%).
How has SomnoMed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SOM has a high level of non-cash earnings.
Growing Profit Margin: SOM's current net profit margins (1.3%) are lower than last year (5.8%).
Past Earnings Growth Analysis
Earnings Trend: SOM's earnings have grown by 10.5% per year over the past 5 years.
Accelerating Growth: SOM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SOM had negative earnings growth (-75.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (14.7%).
Return on Equity
High ROE: SOM's Return on Equity (4.1%) is considered low.
How is SomnoMed's financial position?
Financial Position Analysis
Short Term Liabilities: SOM's short term assets (A$22.7M) exceed its short term liabilities (A$17.0M).
Long Term Liabilities: SOM's short term assets (A$22.7M) exceed its long term liabilities (A$5.6M).
Debt to Equity History and Analysis
Debt Level: SOM's debt to equity ratio (16.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if SOM's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: SOM's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: SOM's interest payments on its debt are well covered by EBIT (7.6x coverage).
Inventory Level: SOM has a high level of physical assets or inventory.
Debt Coverage by Assets: SOM's debt is covered by short term assets (assets are 6.8x debt).
What is SomnoMed's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SOM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SOM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SOM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SOM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SOM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Neil Verdal-Austin has been the Chief Executive of SomnoMed Limited since November 19, 2018. Mr. Verdal-Austin served as Chief Financial Officer of SomnoMed Limited since October 15, 2008 until Novembe ...
CEO Compensation Analysis
Compensation vs Market: Neil's total compensation ($USD285.63K) is about average for companies of similar size in the Australian market ($USD239.28K).
Compensation vs Earnings: Neil's compensation has been consistent with company performance over the past year.
|Chief Executive Officer||1.42yrs||AU$471.88k||1.58% A$1.3m|
|Chief Financial Officer||1yr||AU$267.23k||0.027% A$22.0k|
|Executive Vice President of Sales and Marketing - Europe||no data||AU$513.08k||0.63% A$522.5k|
|Executive President of North America||7.42yrs||AU$658.71k||1.36% A$1.1m|
|Chief Medical Officer||no data||no data||no data|
|Company Secretary||25.25yrs||AU$10.56k||no data|
|General Manager of Operations||no data||AU$8.96k||no data|
|Vice President of Global Production and Product Development||no data||AU$128.07k||no data|
Experienced Management: SOM's management team is considered experienced (4.4 years average tenure).
|Member of the Medical Advisory Board||no data||no data||no data|
|Member of the Medical Advisory Board||no data||no data||no data|
|Chairman of the Medical Advisory Board||no data||no data||no data|
|Non-Executive Chairman||7.83yrs||AU$238.81k||1.1% A$909.6k|
|Non-Executive Director||8.58yrs||AU$65.56k||0.18% A$150.8k|
|Non-Executive Director||1.92yrs||AU$65.56k||no data|
|Non-Executive Director||8.58yrs||AU$65.56k||0.12% A$100.6k|
Experienced Board: SOM's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SomnoMed Limited's company bio, employee growth, exchange listings and data sources
- Name: SomnoMed Limited
- Ticker: SOM
- Exchange: ASX
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$82.381m
- Shares outstanding: 74.89m
- Website: https://somnomed.com/au/
Number of Employees
- SomnoMed Limited
- 20 Clarke Street
- Level 3
- Crows Nest
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SOMAO||ASX (Australian Securities Exchange)||NPV DFD 22/04/20(EX-RIGHTS)||AU||AUD||No data|
|SOM||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Aug 2004|
|SOMN.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Aug 2004|
|SOM||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Aug 2004|
|RJV||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Aug 2004|
SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Australia and internationally. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/05 10:33|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.